Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 162

1.

Topical E6005, a novel phosphodiesterase 4 inhibitor, attenuates spontaneous itch-related responses in mice with chronic atopy-like dermatitis.

Andoh T, Yoshida T, Kuraishi Y.

Exp Dermatol. 2014 May;23(5):359-61. doi: 10.1111/exd.12377.

PMID:
24645735
2.
3.

Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model.

Ishii N, Shirato M, Wakita H, Miyazaki K, Takase Y, Asano O, Kusano K, Yamamoto E, Inoue C, Hishinuma I.

J Pharmacol Exp Ther. 2013 Jul;346(1):105-12. doi: 10.1124/jpet.113.205542. Epub 2013 May 14.

4.

A putative antipruritic mechanism of the phosphodiesterase-4 inhibitor E6005 by attenuating capsaicin-induced depolarization of C-fibre nerves.

Wakita H, Ohkuro M, Ishii N, Hishinuma I, Shirato M.

Exp Dermatol. 2015 Mar;24(3):215-6. doi: 10.1111/exd.12606.

PMID:
25431172
5.

Effect of the phosphodiesterase 4 inhibitor E6005 on nerve growth factor elevation in irritated skin of NC/Nga mice.

Ishii N, Wakita H, Shirato M.

J Dermatol Sci. 2014 Dec;76(3):263-4. doi: 10.1016/j.jdermsci.2014.09.010. Epub 2014 Nov 6. No abstract available.

PMID:
25455141
6.

The anti-pruritic efficacy of TS-022, a prostanoid DP1 receptor agonist, is dependent on the endogenous prostaglandin D2 level in the skin of NC/Nga mice.

Sugimoto M, Arai I, Futaki N, Hashimoto Y, Sakurai T, Honma Y, Nakaike S.

Eur J Pharmacol. 2007 Jun 14;564(1-3):196-203. Epub 2007 Feb 8.

PMID:
17328887
7.

Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: results of a randomized, vehicle-controlled, multicenter clinical trial.

Furue M, Kitahara Y, Akama H, Hojo S, Hayashi N, Nakagawa H; JAPANESE E6005 Study Investigators..

J Dermatol. 2014 Jul;41(7):577-85. doi: 10.1111/1346-8138.12534. Epub 2014 Jun 18.

PMID:
24942594
8.

Efficacy of a novel phosphodiesterase inhibitor, E6005, in patients with atopic dermatitis: An investigator-blinded, vehicle-controlled study.

Ohba F, Matsuki S, Imayama S, Matsuguma K, Hojo S, Nomoto M, Akama H.

J Dermatolog Treat. 2016 Oct;27(5):467-72. doi: 10.3109/09546634.2016.1157257. Epub 2016 Apr 14.

PMID:
27080209
9.

Effects of TS-022, a newly developed prostanoid DP1 receptor agonist, on experimental pruritus, cutaneous barrier disruptions and atopic dermatitis in mice.

Arai I, Takaoka A, Hashimoto Y, Honma Y, Koizumi C, Futaki N, Sugimoto M, Takahashi N, Inoue T, Nakanishi Y, Sakurai T, Tanami T, Yagi M, Ono N, Nakaike S.

Eur J Pharmacol. 2007 Feb 5;556(1-3):207-14. Epub 2006 Nov 3.

PMID:
17141215
10.
11.

Safety, tolerability and pharmacokinetics of a novel phosphodiesterase inhibitor, E6005 ointment, in healthy volunteers and in patients with atopic dermatitis.

Ohba F, Nomoto M, Hojo S, Akama H.

J Dermatolog Treat. 2016;27(3):241-6. doi: 10.3109/09546634.2015.1093587. Epub 2015 Nov 18.

PMID:
26581111
12.

An inhaled phosphodiesterase 4 inhibitor E6005 suppresses pulmonary inflammation in mice.

Kubota S, Watanabe M, Shirato M, Okuno T, Higashimoto I, Machida K, Yokomizo T, Inoue H.

Eur J Pharmacol. 2015 Dec 5;768:41-8. doi: 10.1016/j.ejphar.2015.10.013. Epub 2015 Oct 8.

PMID:
26455478
13.

Possible Antipruritic Mechanism of Cyclosporine A in Atopic Dermatitis.

Ko KC, Tominaga M, Kamata Y, Umehara Y, Matsuda H, Takahashi N, Kina K, Ogawa M, Ogawa H, Takamori K.

Acta Derm Venereol. 2016 Jun 15;96(5):624-9. doi: 10.2340/00015555-2318.

14.

Inhibition of scratching behavior associated with allergic dermatitis in mice by tacrolimus, but not by dexamethasone.

Inagaki N, Shiraishi N, Igeta K, Itoh T, Chikumoto T, Nagao M, Kim JF, Nagai H.

Eur J Pharmacol. 2006 Sep 28;546(1-3):189-96. Epub 2006 Jul 25.

PMID:
16914137
15.

Oral chymase inhibitor SUN13834 ameliorates skin inflammation as well as pruritus in mouse model for atopic dermatitis.

Terakawa M, Fujieda Y, Tomimori Y, Muto T, Tanaka T, Maruoka H, Nagahira K, Ogata A, Nakatsuka T, Fukuda Y.

Eur J Pharmacol. 2008 Dec 28;601(1-3):186-91. doi: 10.1016/j.ejphar.2008.10.040. Epub 2008 Oct 29.

PMID:
18996112
16.

Oral administration of bepotastine besilate suppressed scratching behavior of atopic dermatitis model NC/Nga mice.

Tanizaki H, Kambe N, Nakamura Y, Tanaka A, Matsuda H, Miyachi Y.

Int Arch Allergy Immunol. 2008;145(4):277-82. Epub 2007 Nov 13.

PMID:
18004068
17.

New therapies for controlling atopic itch.

Furue M, Kadono T.

J Dermatol. 2015 Sep;42(9):847-50. doi: 10.1111/1346-8138.13060. Review.

PMID:
26332459
18.

Neurotropin suppresses itch-related behavior in NC/Nga mice with atopic dermatitis-like symptoms.

Kamo A, Tominaga M, Matsuda H, Kina K, Kamata Y, Umehara Y, Ogawa H, Takamori K.

J Dermatol Sci. 2016 Mar;81(3):212-5. doi: 10.1016/j.jdermsci.2015.11.014. Epub 2015 Dec 2. No abstract available.

PMID:
26725918
19.

Antipruritic effects of Sophora flavescens on acute and chronic itch-related responses in mice.

Yamaguchi-Miyamoto T, Kawasuji T, Kuraishi Y, Suzuki H.

Biol Pharm Bull. 2003 May;26(5):722-4.

20.

Chronically relapsing pruritic dermatitis in the rats treated as neonate with capsaicin; a potential rat model of human atopic dermatitis.

Back SK, Jeong KY, Li C, Lee J, Lee SB, Na HS.

J Dermatol Sci. 2012 Aug;67(2):111-9. doi: 10.1016/j.jdermsci.2012.05.006. Epub 2012 May 28.

PMID:
22721998

Supplemental Content

Support Center